Pharmaceutical CAS 104987-11-3 Tacrolimus Purity Tacrolimus Powder Tacrolimus

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-sung Tacrolimus
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Product Name: Tacrolimus
• Name: Tacrolimus Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 104987-11-3
• Mf: C44 H69 N O12
• MW: 804.02
• Melting Point: 113-115 C
• Boiling Point: 871.7 C
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 1000kg/Month

Product Description

Pharmaceutical CAS 104987-11-3 Tacrolimus Purity Tacrolimus Powder Tacrolimus

Product Description

Product Details

 

Product Name	Tacrolimus
CAS NO.	104987-11-3
Purity	99%
Density	1.19
Appearance and shape	White powder

Tacrolimus, also known as FK506, is a fermentation product isolated from Streptomyces. It is a macrolide antibiotic and a powerful new immunosuppressant, mainly by inhibiting interleukin-2 The release of (IL-2) completely inhibits the effect of T lymphocytes, which is 100 times stronger than cyclosporine (CsA). In recent years, as a first-line drug for liver and kidney transplantation, it has been marketed in 14 countries including Japan and the United States. Clinical experiments show that it has a good effect in transplantation of heart, lung, intestine, bone marrow, etc. At the same time, FK506 also plays an active role in the treatment of atopic dermatitis (AD), systemic lupus erythematosus (SLE), autoimmune eye disease and other autoimmune diseases.

Application&Function

Function
1.Tacrolimus is used to treat atopic dermatitis (more commonly known as eczema). It is a topical medication which is normally prescribed for patients who have not responded successfully to other eczema medication.
2.Tacrolimus is a type of topical calcineurin inhibitor (TCIs) that works by weakening the patient`s immune system, which as a consequence directly reduces the severity of eczema and its symptoms. It should not be used by patients who have any kind of weak immune system.
Applications
1.The mechanism of action of tacrolimus in atopic dermatitis is not known.  the clinical significance of these observations in atopic dermatitis is not known. It has been demonstrated that tacrolimus inhibits T-lymphocyte activation by first binding to an intracellular protein, FKBP-12.
2.A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the dephosphorylation and translocation of nuclear factor of activated T-cells (NF-AT), a nuclear component thought to initiate gene transcription for the formation of lymphokines.
3.Tacrolimus also inhibits the transcription for genes which encode IL-3, IL-4, IL-5, GM-CSF, and TNF-, all of which are involved in the early stages of T-cell activation. Additionally, tacrolimus has been shown to inhibit the release of pre-formed mediators from skin mast cells and basophils, and to downregulate the expression of FceRI on Langerhans cells.

Specification